Journal ArticleDOI
A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver
Raluca Pais,Frédéric Charlotte,Larissa Fedchuk,Pierre Bedossa,Pascal Lebray,Thierry Poynard,Vlad Ratziu +6 more
TLDR
A substantial proportion of patients with NAFL can progress towards well-defined NASH with bridging fibrosis, especially if metabolic risk factors deteriorate, and current monitoring practices of these patients should be revised.About:
This article is published in Journal of Hepatology.The article was published on 2013-09-01. It has received 417 citations till now. The article focuses on the topics: Fatty liver & Steatohepatitis.read more
Citations
More filters
Journal ArticleDOI
Natural history of nonalcoholic fatty liver disease: A prospective follow-up study with serial biopsies.
TL;DR: NAFLD is a highly heterogeneous disease, and it is surprisingly hard to predict fibrosis progression, with 16% of patients with fibrosis stage <3 developing advanced fibrosis and 9.3% showing signs of end‐stage liver disease.
Journal ArticleDOI
Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity?
Judith Aron-Wisnewsky,Judith Aron-Wisnewsky,Moritz V. Warmbrunn,Max Nieuwdorp,Karine Clément +4 more
TL;DR: How probiotics, prebiotics, synbiotic, fecal microbiota transfer, polyphenols, specific diets and exercise interventions have been shown to modify gut microbiota signatures, improve NAFLD outcomes is discussed and detail, when available, the different mechanisms by which these beneficial outcomes might occur is discussed.
Journal ArticleDOI
Myeloid Sirtuin 6 Deficiency Causes Insulin Resistance in High-Fat Diet–Fed Mice by Eliciting Macrophage Polarization Toward an M1 Phenotype
Youngyi Lee,Sun-O Ka,Hye-Na Cha,Yu-Na Chae,Mi-Kyung Kim,So-Young Park,Eun Ju Bae,Byung-Hyun Park +7 more
TL;DR: It is concluded that Sirt6 in macrophages is required for the prevention of obesity-associated tissue inflammation and insulin resistance.
Journal ArticleDOI
Downregulation of microRNA-451 in non-alcoholic steatohepatitis inhibits fatty acid-induced proinflammatory cytokine production through the AMPK/AKT pathway
Wonhee Hur,Joon Ho Lee,Sung Woo Kim,Jung-Hee Kim,Si Hyun Bae,Minhyung Kim,Daehee Hwang,Daehee Hwang,Young Seok Kim,Taesun Park,Soo-Jong Um,Byoung Joon Song,Seung Kew Yoon +12 more
TL;DR: In vitro analysis of the effect of miR-451 on proinflammatory cytokine provided evidence for negative regulation of PA-induced interleukin (IL)-8 and tumor necrosis factor-alpha (TNF-α) production and showed that Cab39 is a direct target of miRNA-451 in steatotic cells, while study showed that AMPK activated through Cab39 inhibits NF-κB transactivation induced in Steatotic HepG2 cells.
Journal ArticleDOI
Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease
Pierre Bedossa,Keyur Patel +1 more
TL;DR: Improved understanding of the pathophysiology of NAFLD and technologic advances have led to algorithms that can be used to assess serum biomarkers and imaging methods that are noninvasive alternatives to biopsy collection and analysis.
References
More filters
Journal ArticleDOI
Design and validation of a histological scoring system for nonalcoholic fatty liver disease
David E. Kleiner,Elizabeth M. Brunt,Mark L. Van Natta,Cynthia Behling,Melissa J. Contos,Oscar W. Cummings,Linda D. Ferrell,Yao Chang Liu,Michael Torbenson,Aynur Unalp-Arida,Matthew M. Yeh,Arthur J. McCullough,Arun J. Sanyal +12 more
TL;DR: A strong scoring system and NAS for NAFLD and NASH with reasonable inter‐rater reproducibility that should be useful for studies of both adults and children with any degree ofNAFLD are presented.
Journal ArticleDOI
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
Naga Chalasani,Zobair M. Younossi,Joel E. Lavine,Anna Mae Diehl,Elizabeth M. Brunt,Kenneth Cusi,Michael Charlton,Arun J. Sanyal +7 more
TL;DR: This is a practice guideline for clinicians rather than a review article and interested readers can refer to several comprehensive reviews published recently.
Journal ArticleDOI
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
Christi A. Matteoni,Zobair M. Younossi,Terry Gramlich,Navdeep Boparai,Yao Chang Liu,Arthur J. McCullough +5 more
TL;DR: The outcome of cirrhosis and liver-related death is not uniform across the spectrum of nonalcoholic fatty liver, and poor outcomes are more frequent in patients in whom biopsies show ballooning degeneration and Mallory hyaline or fibrosis.
Journal ArticleDOI
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Leon A. Adams,James F. Lymp,Jenny St. Sauver,Schuyler O. Sanderson,Keith D. Lindor,Ariel E. Feldstein,Paul Angulo +6 more
TL;DR: Mortality among community-diagnosed NAFLD patients is higher than the general population and is associated with older age, impaired fasting glucose, and cirrhosis, although the absolute risk is low.
Journal ArticleDOI
Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome
Giulio Marchesini,Elisabetta Bugianesi,Gabriele Forlani,Fernanda Cerrelli,Marco Lenzi,R. Manini,S. Natale,Ester Vanni,Nicola Villanova,Nazario Melchionda,Mario Rizzetto +10 more
TL;DR: The presence of multiple metabolic disorders is associated with a potentially progressive, severe liver disease and the increasing prevalence of obesity, coupled with diabetes, dyslipidemia, hypertension, and ultimately the metabolic syndrome puts a very large population at risk of forthcoming liver failure in the next decades.